

119TH CONGRESS  
1ST SESSION

# H. R. 661

To require the Secretary of Health and Human Services, in consultation with the Secretary of Commerce, the Council for Technology and Innovation of the Centers for Medicare & Medicaid Services, and the Commissioner of Food and Drugs, to carry out a program to facilitate and coordinate efforts between the United States and Israel to expand and enhance collaboration on the development and delivery of health care products and services.

---

## IN THE HOUSE OF REPRESENTATIVES

JANUARY 23, 2025

Mr. BUCHANAN (for himself, Mr. SOTO, and Mrs. MILLER-MEEKS) introduced the following bill; which was referred to the Committee on Energy and Commerce

---

## A BILL

To require the Secretary of Health and Human Services, in consultation with the Secretary of Commerce, the Council for Technology and Innovation of the Centers for Medicare & Medicaid Services, and the Commissioner of Food and Drugs, to carry out a program to facilitate and coordinate efforts between the United States and Israel to expand and enhance collaboration on the development and delivery of health care products and services.

1        *Be it enacted by the Senate and House of Representa-*  
2        *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Maximizing Israel-U.S.  
3 Research Advancement and Collaborative Leadership in  
4 Emerging Medical Technology Act of 2025” or the “MIR-  
5 ACLE Medical Technology Act of 2025”.

6 **SEC. 2. PROGRAM FOR FACILITATION AND COORDINATION**  
7 **OF UNITED STATES-ISRAEL EFFORTS ON THE**  
8 **DEVELOPMENT AND DELIVERY OF HEALTH**  
9 **CARE PRODUCTS AND SERVICES.**

10 (a) IN GENERAL.—Subject to the availability of ap-  
11 propriations, the Secretary of Health and Human Serv-  
12 ices, in consultation with the Secretary of Commerce, the  
13 Council for Technology and Innovation of the Centers for  
14 Medicare & Medicaid Services, and the Commissioner of  
15 Food and Drugs, shall carry out a program to facilitate  
16 and coordinate efforts between the United States and  
17 Israel to expand and enhance collaboration on—

18 (1) the development of health care products and  
19 services; and

20 (2) the delivery of such products and services to  
21 those in need.

22 (b) PROGRAM COMPONENTS.—The program under  
23 subsection (a) shall include facilitation and coordination  
24 of efforts including each of the following:

25 (1) RESEARCH AND DEVELOPMENT.—

1 (A) Joint research projects between United  
2 States and Israeli institutions and companies.

3 (B) Promoting collaboration in areas such  
4 as medical device technology, pharmaceuticals  
5 (including biological products, genomics, and in-  
6 novative digital health care solutions), and  
7 health care systems management, including a  
8 special focus on early-stage clinical trials.

9 (C) With respect to biological products,  
10 supporting—

11 (i) innovation;

12 (ii) process optimization; and

13 (iii) the development of advanced  
14 manufacturing techniques that can en-  
15 hance productivity, reduce costs, and im-  
16 prove product quality.

17 (D) Work toward developing a framework  
18 for sharing health data for research purposes  
19 with the Ministry of Health of Israel.

20 (2) INNOVATION AND START-UP ECOSYSTEM.—

21 (A) Fostering collaboration between United  
22 States and Israeli start-up and other companies  
23 in the health care sector.

24 (B) Facilitating innovative technology ac-  
25 ceptance by the marketplace.

1 (C) Facilitating mechanisms for technology  
2 transfer and joint venture opportunities.

3 (D) Supporting innovation hubs to accel-  
4 erate the development and commercialization of  
5 United States health care technologies in the  
6 Israeli market, including by encouraging cyber-  
7 security standards for sharing data, promoting  
8 patient privacy, and encouraging research.

9 (3) REGULATORY HARMONIZATION AND INTEL-  
10 LECTUAL PROPERTY PROTECTION.—Establishing  
11 joint efforts—

12 (A) to ensure intellectual property protec-  
13 tion;

14 (B) to increase regulatory harmonization,  
15 including with respect to regulatory data pro-  
16 tection for biological products;

17 (C) to formulate plans for a commer-  
18 cialization framework for medical device tech-  
19 nologies;

20 (D) to encourage a potential mutual rec-  
21 ognition agreement for pharmaceutical good  
22 manufacturing Practices between the Food and  
23 Drug Administration and Israeli regulators;

24 (E) to strengthen and reaffirm the con-  
25 fidentiality commitment with the Food and

1 Drug Administration and the Pharmaceutical  
2 Division, the Medical Devices Department, and  
3 the National Food Services and Nutrition Divi-  
4 sion of the Ministry of Health of Israel;

5 (F) to encourage Israel’s participation in  
6 regulatory harmonization and cooperation orga-  
7 nizations; and

8 (G) to expand international collaboration  
9 under Project Orbis for concurrent submission  
10 and review of oncology products.

11 (4) HEALTH CARE SYSTEM STRENGTHENING.—  
12 Facilitating the sharing of best practices, knowledge,  
13 and skills in areas such as clinical care and health  
14 care management.

15 (5) TELEMEDICINE AND DIGITAL HEALTH CO-  
16 OPERATION.—Establishing initiatives—

17 (A) to enhance telemedicine infrastructure;

18 (B) to promote interoperability between  
19 United States and Israeli health care systems;  
20 and

21 (C) to facilitate collaboration on digital  
22 health technologies, data analytics, and cyberse-  
23 curity.

24 (6) DISEASE PREVENTION INITIATIVES.—Col-  
25 laborating in disease prevention, including joint ef-

1       forts to combat infectious diseases, develop vaccines,  
2       and share epidemiological data.

3               (7) BIOLOGICAL PRODUCT MANUFACTURING.—

4                       (A) Promoting biological product manufac-  
5                       turing.

6                       (B) Establishing joint manufacturing fa-  
7                       cilities for biological products in facilities in the  
8                       United States that leverage the strengths and  
9                       expertise of both countries.

10                      (C) Pursuing accelerated development of  
11                      life-saving treatments and new sources of nutri-  
12                      tion that are both healthier and more available  
13                      at an affordable cost.

14                      (D) Workforce training and skill develop-  
15                      ment, including promoting exchange programs  
16                      and training initiatives to develop a skilled  
17                      workforce in biological product manufacturing.

18                      (E) Supply chain resilience through stra-  
19                      tegic collaboration to identify and develop con-  
20                      tingency plans to mitigate biological product  
21                      supply disruptions.

22                      (F) Facilitating public-private partnerships  
23                      to support the development and scale-up of bio-  
24                      logical product manufacturing capabilities.

1           (c) UNITED STATES-ISRAEL HEALTH CARE COL-  
2 LABORATION CENTER.—In carrying out the program  
3 under subsection (a), the Secretary of Health and Human  
4 Services may establish a joint United States-Israel Health  
5 Care Collaboration Center in the United States leveraging  
6 the experience, knowledge, and expertise of institutions of  
7 higher education, national laboratories, entities in the pri-  
8 vate sector, and others in the development and delivery  
9 of health care products and services.

10          (d) COMMENCEMENT OF IMPLEMENTATION.—Not  
11 later than 6 months after the date of enactment of this  
12 Act, the Secretary of Health and Human Services shall  
13 commence implementation of the program under this sec-  
14 tion.

15          (e) AUTHORIZATION OF APPROPRIATIONS.—To carry  
16 out this Act, there is authorized to be appropriated  
17 \$8,000,000 for each of fiscal years 2026 through 2030.

○